Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease

Annals of Clinical and Translational Neurology

Volumn 2, Issue 10, 2015, Pages 949-959

  Buddhala, Chandana ^a   Loftin, Susan K ^a   Kuley, Brandon M ^a   Cairns, Nigel J ^a   Campbell, Meghan C ^a   Perlmutter, Joel S ^a   Kotzbauer, Paul T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; NORADRENALIN; SEROTONIN; SEROTONIN TRANSPORTER; VESICULAR ACETYLCHOLINE TRANSPORTER;

AMYGDALA; ARTICLE; AUTOPSY; BRAIN TISSUE; CAUDATE NUCLEUS; CHOLINERGIC NERVE CELL; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFERIOR PARIETAL LOBULE; INNERVATION; LOCUS CERULEUS; MALE; MEYNERT BASAL NUCLEUS; MIDDLE FRONTAL GYRUS; NORADRENERGIC NERVE CELL; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; PRECUNEUS; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA PARS COMPACTA; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL CORTEX; WESTERN BLOTTING;

EID: 85015593783     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.246     Document Type: Article

References (53)

1. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469–6473.
2. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121–134.
3. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011;221:564–573.
4. Gesi M, Soldani P, Giorgi FS, et al. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 2000;24:655–668.
5. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007;14:523–528.
6. Bosboom JL, Stoffers D, Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004;111:1303–1315.
7. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134(Pt 5):1493–1505.
8. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–844.
9. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916–1921.
10. Bosboom JL, Stoffers D, Wolters E. The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease. J Neural Transm Suppl 2003;65:185–195.
11. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014;29:634–650.
12. Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res 2013;230:463–476.
13. Riekkinen M, Kejonen K, Jakala P, et al. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 1998;10:1429–1435.
14. Sawamoto N, Piccini P, Hotton G, et al. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008;131(Pt 5):1294–1302.
15. Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 1998;39:1521–1530.
16. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131(Pt 1):120–131.
17. Shannak K, Rajput A, Rozdilsky B, et al. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 1994;639:33–41.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
19. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689–1707; quiz 837.
20. Cairns NJ, Taylor-Reinwald L, Morris JC; Alzheimer's Disease Neuroimaging I. Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement 2010;6:274–279.
21. Nieuwenhuys R, Voogd J, Huijzen CV. The human central nervous system: a synopsis and atlas. 3rd rev. ed. Berlin, New York: Springer, 1988.
22. Xia Y, Cheng S, He J, et al. Effects of subchronic exposure to benzo[a]pyrene (B[a]P) on learning and memory, and neurotransmitters in male Sprague–Dawley rat. Neurotoxicology 2011;32:188–198.
23. Worsley JN, Moszczynska A, Falardeau P, et al. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry 2000;5:664–672.
24. Engel LA, Jing Z, O'Brien DE, et al. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One 2010;5:e12897.
25. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.
26. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326–1331.
27. Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125(Pt 3):584–594.
28. Daws LC. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 2009;121:89–99.
29. Harik SI, LaManna JC, Light AI, Rosenthal M. Cerebral norepinephrine: influence on cortical oxidative metabolism in situ. Science 1979;206:69–71.
30. Powers WJ, Videen TO, Markham J, et al. Cerebral mitochondrial metabolism in early Parkinson's disease. J Cereb Blood Flow Metab 2008;28:1754–1760.
31. Heneka MT, Galea E, Gavriluyk V, et al. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci 2002;22:2434–2442.
32. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 2004;45:38–78.
33. O'Donnell J, Zeppenfeld D, McConnell E, et al. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 2012;37:2496–2512.
34. Mizukawa K, McGeer EG, McGeer PL. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, Alzheimer disease, and neurologically normal controls. Mol Chem Neuropathol 1993;18:133–144.
35. Miller GW, Staley JK, Heilman CJ, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997;41:530–539.
36. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133–140.
37. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718–726.
38. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321–328.
39. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003;60:1223–1229.
40. Haapaniemi TH, Ahonen A, Torniainen P, et al. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001;16:124–130.
41. Goldstein DS, Sullivan P, Holmes C, et al. Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 2011;18:703–710.
42. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399–410.
43. Petrou M, Frey KA, Kilbourn MR, et al. In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J Nucl Med 2014;55:396–404.
44. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128(Pt 6):1314–1322.
45. Berding G, Brucke T, Odin P, et al. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin 2003;42:31–38.
46. Gaspar P, Gray F. Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta Neuropathol 1984;64:43–52.
47. Siegal D, Erickson J, Varoqui H, et al. Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse 2004;52:223–232.
48. Lubomski M, Louise Rushworth R, Lee W, et al. Sex differences in Parkinson's disease. J Clin Neurosci 2014;21:1503–1506.
49. Smith KM, Dahodwala N. Sex differences in Parkinson's disease and other movement disorders. Exp Neurol 2014;259:44–56.
50. Huang Y, Zheng MQ, Gerdes JM. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem 2010;10:1499–1526.
51. Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006;10:167–179.
52. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288–295.
53. Runyon SP, Carroll FI. Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem 2006;6:1825–1843.